Dublin-based clinical biopharmaceutical company Amarin has announced full-year results for 2010 which reveal that it has strengthened its balance sheet with additional $98.7 million (€70.4 million) in cash.
The Nasdaq-listed company, which is at clinical-stage and is thus pre-revenue, said that its cash and cash equivalents balance at the end of 2010 was $31.4 million, compared to $52.3 million a year earlier.
The company booked a net loss for the year of $249.6 million last year, up from a loss...
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Unlimited Access for 2 Years
Get a Business Account for you and your team